Download PDF
Exp Clin Endocrinol Diabetes 1987; 90(5): 185-189
DOI: 10.1055/s-0029-1210688
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Prevention of the Anovulatory Syndrome and Testosterone-Induced Rise in Catecholamine Level in the Hypothalamus of Newborn Rats with Steroid Aromatase Inhibitors

A. G. Reznikov, N. D. Nosenko
  • Laboratory of Neurohormonal Control of Reproduction (Head: Prof. A. G. Reznikov), Research Institute of Endocrinology and Metabolism (Director: Dr. med. sci. N. D. Tronko) Kiev/USSR
Further Information

Publication History

1986

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Testosterone propionate administration in a dose of 50 μg on the 5th day of the postnatal life did not change hypothalamic noradrenaline and dopamine levels in female rats on the 7th, 8th, 12th days of life but increased it significantly in 10-day-old animals. This rise was completely prevented by steroid aromatase inhibitors (4-androstene-3,16,17-trione, 0.5 mg or 1,4,6-andro-statriene-3,17-dione, 1 mg per animal) on the 5th or 7th days of life. Aromatase inhibitors reduced the anovulatory syndrome occurrence in neonatally androgenized rats from 93% to 15—17%.

The data obtained prove the importance of testosterone conversion into estrogen for sexual brain differentiation. They support authors' hypothesis that testosterone-induced rise of hypothalamic catecholamine content in newborn female rats is evoked by the estrogen metabolites of testosterone.

Key words

Androgen - Steroid aromatase - Catecholamine - Brain differentiation